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Elevated serum urate levels cause gout and correlate with cardio-metabolic diseases via 340 
poorly understood mechanisms. We performed a trans-ethnic genome-wide association 341 
study of serum urate among 457,690 individuals, identifying 183 loci (147 novel) that improve 342 
prediction of gout in an independent cohort of 334,880 individuals. Serum urate showed 343 
significant genetic correlations with many cardio-metabolic traits, with genetic causality 344 
analyses supporting a substantial role for pleiotropy. Enrichment analysis, fine-mapping of 345 
urate-associated loci, and co-localization with gene expression in 47 tissues implicated kidney 346 
and liver as main target organs and prioritized potentially causal genes and variants, including 347 
the transcriptional master regulators in liver and kidney, HNF1A and HNF4A. Experimental 348 
validation showed that HNF4A trans-activated the promoter of the major urate transporter 349 
ABCG2 in kidney cells, and that HNF4A p.Thr139Ile is a functional variant. Transcriptional co-350 
regulation within and across organs may be a general mechanism underlying the observed 351 
pleiotropy between urate and cardio-metabolic traits. 352 
 353 
Serum urate levels reflect a balance between uric acid production and its renal and intestinal 354 
excretion. Elevated serum urate levels define hyperuricemia, which is associated with 355 
metabolic, cardiovascular and kidney-related conditions. Hyperuricemia can cause kidney 356 
stones and gout, the most common inflammatory arthritis1,2. Gout attacks are a highly painful 357 
response to the deposition of urate crystals, and are a significant cause of morbidity and related 358 
health care costs3. Although gout has become a major public health issue, it is undertreated 359 
due to low awareness, poor patient adherence4, and inappropriate prescription practices of the 360 
most commonly used drug, allopurinol5. A better understanding of the mechanisms controlling 361 
serum urate may help to develop novel medications for gout treatment and prevention and 362 
provide insights into regulatory mechanisms shared between urate and cardio-metabolic traits.  363 
Heritability of serum urate varies between 30% and 60%6-11. Candidate gene and 364 
genome-wide associations studies (GWAS) have identified three genes as major determinants 365 
of urate levels: SLC2A9, ABCG2, and SLC22A127,12-18. While SLC2A9 and ABCG2 harbor common 366 
variants of relatively large effect19, SLC22A12 contains many rare or low-frequency variants20. 367 
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The largest GWAS meta-analyses performed to date identified 28 loci among European ancestry 368 
(EA)21 and 27 among Japanese individuals22. Many genes in the associated loci encode renal and 369 
intestinal urate transporters or their regulators, while others are relevant to glucose and lipid 370 
metabolism, functions of the liver, where uric acid is generated. With increased public 371 
availability of large annotation and gene expression datasets23,24, fine-mapping associated loci 372 
to prioritize target tissues, pathways, and potentially causal genes and variants has become 373 
possible. 374 
Here, we perform a trans-ethnic meta-analysis of GWAS of serum urate among 457,690 375 
individuals and identify 183 associated loci that improve gout risk prediction in an independent 376 
sample of 334,880 UK Biobank (UKBB) participants. We evaluate the genetic correlation of 377 
serum urate with hundreds of cardio-metabolic traits and diseases, and use a recently 378 
developed latent causal variable model to examine the contribution of causality versus 379 
pleiotropy. We prioritize target variants, genes, tissues and pathways that contribute to the 380 
complex regulation of urate levels through comprehensive data integration. Lastly, we conduct 381 
proof-of-principle experimental studies showing that HNF4A, a transcriptional master regulator 382 
in liver and kidney proximal tubule, can regulate transcription of the major urate transporter 383 
ABCG2 in kidney cells and that the fine-mapped HNF4A variant p.Thr139Ile is functional. 384 
Transcriptional co-regulation of processes linked to energy metabolism within and across 385 
organs may underlie the pleiotropy observed between urate levels and numerous cardio-386 
metabolic traits.  387 
 388 
Results 389 
Trans-ethnic meta-analysis identifies 183 urate-associated loci 390 
Trans-ethnic meta-analyses were conducted to maximize the sample size for locus discovery, 391 
and EA-specific analyses were used where population-specific linkage disequilibrium (LD) was 392 
required to characterize loci (Supplementary Fig. 1). The primary trans-ethnic meta-analysis 393 
included 457,690 individuals (EA, n = 288,649; East Asian ancestry (EAS), n = 125,725; African 394 
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Americans (AA), n = 33,671; South Asian ancestry (SA), n = 9,037; and Hispanics (HIS), n = 608) 395 
from 74 studies. Mean urate levels ranged from 4.2 to 7.2 mg/dl (Supplementary Table 1). 396 
GWAS were performed based on genotypes imputed using the 1000 Genomes Project or 397 
Haplotype Reference Consortium reference panels (Methods and Supplementary Table 2). 398 
Results were combined through inverse-variance weighted fixed effect meta-analysis after 399 
central study-specific quality control. There was no evidence of inflation due to unmodeled 400 
population structure (LD score regression intercept = 1.01; genomic inflation factor λGC = 1.04). 401 
Post-meta-analysis variant filtering left 8,249,849 high-quality SNPs for downstream analyses 402 
(Methods).  403 
We identified 183 loci that contained at least one genome-wide significant SNP (P ≤ 5 x 404 
10-8, Fig. 1 and Supplementary Table 3). Of these, 36 contained an index SNP reported in 405 
previous GWAS of serum urate13,15,17,18,21,22,25,26, and 147 were considered novel (Fig. 1). Allelic 406 
effects on serum urate ranged from 0.28 to 0.017 mg/dl (mean 0.038 mg/dl, standard deviation 407 
(SD) 0.033). Regional association plots are shown in the Supplementary Data Set.  408 
The index SNPs at all 183 loci explained 7.7% of the serum urate variance (Methods), 409 
compared to 5.3% explained by index SNPs previously reported from GWAS in EA populations21. 410 
In a large participating general population-based pedigree study, the 183 index SNPs explained 411 
17% of serum urate genetic heritability (h2 = 37%, 95% credible interval: 29%, 45%), with 5% 412 
attributed to the index SNPs at SLC2A9, ABCG2 and SLC22A12 (Supplementary Fig. 2 and 413 
Methods). 414 
 415 
Characterization of ancestry-related heterogeneity 416 
For the 183 index SNPs, we observed no evidence of systematic between-study heterogeneity 417 
(median I2 = 2%, interquartile range 0-14%; Supplementary Table 3). Fourteen index SNPs 418 
showed significant evidence of ancestry-associated heterogeneity (Panc-het < 2.7 x 10-4 = 419 
0.05/183) when tested using meta-regression (Supplementary Fig. 3 and Methods), consistent 420 
with their higher measures of between-study heterogeneity (I2 > 25%, Fig. 1 and 421 
Supplementary Table 3). The most significant ancestry-associated heterogeneity was observed 422 
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for rs3775947 at SLC2A9 (Panc-het = 1.5 x 10-127, allelic effect 0.34 (EA), 0.26 (AA), 0.17 (EAS), 0.41 423 
(HIS), and 0.21 (SA) mg/dl), consistent with previous reports of population heterogeneity at this 424 
locus27. Nine genome-wide significant loci identified through meta-regression did not overlap 425 
with the 183 loci, including SLC2A2 and KCNQ1 that were genome-wide significant in EAS 426 
(Supplementary Table 4). Ancestry-specific meta-analyses of EA, AA, EAS and SA are 427 
summarized in Supplementary Tables 5-8, respectively, and in the Supplementary Note.  428 
 429 
Sex-stratified meta-analyses of serum urate GWAS  430 
Mean serum urate levels and gout risk are higher in men than in women28. We therefore tested 431 
whether the 183 urate-associated index SNPs showed sex-specific differences. Six SNPs showed 432 
significant effect differences (Pdiff < 2.7 x 10-4 = 0.05/183), at SLC2A9, ABCG2, CAPN1, GCKR, 433 
IDH2, and SLC22A12 (Supplementary Table 9). The genome-wide test for differences in genetic 434 
effects on urate levels between men and women identified only SNPs at SLC2A9 and ABCG2 435 
(Pdiff < 5 x 10-8, Methods and Supplementary Fig. 4), consistent with previous reports7,14,15,21, 436 
and several suggestive loci (Pdiff < 1 x 10-5, Supplementary Table 10).  437 
 438 
Urate index SNPs are associated with gout  439 
We next assessed the association of the 183 trans-ethnic urate index SNPs with gout in a trans-440 
ethnic meta-analysis of 20 studies comprising 763,813 participants with 13,179 gout cases 441 
(Methods, Fig. 1 and Supplementary Table 1). Consistent with the causal role of hyperuricemia 442 
in gout, genetic effects were highly correlated (Spearman correlation coefficient 0.87, 443 
Supplementary Fig. 5a; 0.82 for SNPs with urate association P-values between 5 x 10-8 and 1 x 444 
10-8). Fifty-five SNPs were significantly associated with gout (P < 2.7 x 10-4 = 0.05/183). In 445 
agreement with previous findings29, the largest odds ratio (OR) for gout was observed at ABCG2 446 
(OR 2.04, 95% confidence interval (CI) 1.96-2.12, P = 7.7 x 10-299). Genetic effects were generally 447 
larger among index SNPs with lower minor allele frequency (MAF), with the exception of a few 448 
common large-effect SNPs in known major urate loci SLC2A9, ABCG2, and SLC22A1230 449 
(Supplementary Fig. 5b). 450 
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 451 
A genetic risk score for urate improves gout risk prediction  452 
We evaluated whether a weighted urate genetic risk score (GRS) improved gout risk prediction 453 
when added to demographic information in a large, independent sample of 334,880 UKBB 454 
participants, including 4,908 gout cases (Methods). Across categories of the GRS, gout 455 
prevalence increased from 0.1% to 12.9% (Fig. 2a and Supplementary Table 11). Compared to 456 
the most common GRS category, the age- and sex-adjusted OR of gout ranged from 0.09 (95% 457 
CI 0.02-0.37, P = 7.8 x 10-4) in the lowest to 13.6 (95% CI 7.2-25.7, P = 1.4 x 10-15) in the highest 458 
GRS category (Fig. 2b and Supplementary Table 11). The 3.5% of individuals in the three 459 
highest GRS categories had a >3-fold increase in gout risk compared to individuals in the most 460 
common GRS category. This risk is comparable to a monogenic disease of modest effect size31, 461 
but affects a higher proportion of the population.  462 
We additionally constructed gout risk prediction models in the UKBB sample, which was 463 
not part of the discovery analysis of serum urate-associated variants. Gout status was regressed 464 
on the GRS alone (“genetic model”), on age and sex (“demographic model”), and on the GRS, 465 
age, and sex (“combined model”) in a model development subset of 90% of the individuals to 466 
obtain precise estimates. These models were then used to predict gout status in the remaining 467 
10%, the validation sample. The genetic model was a weaker predictor (area under the receiver 468 
operating characteristic curve (AUC) = 0.68) than the demographic model (AUC = 0.79). 469 
Addition of the GRS (combined model) significantly increased prediction accuracy (AUC = 0.84, 470 
DeLong’s test P < 2.2 x 10-16; Fig. 2c) and achieved a sensitivity of 84% and specificity of 68%. 471 
Ten-fold cross-validation of the regression models provided mean AUCs of 0.67 (s.d. 0.011), 472 
0.78 (s.d. 0.006) and 0.83 (s.d. 0.008) for the genetic, demographic and combined models, 473 
respectively (Methods). The GRS represents a life-long predisposition to higher urate levels and 474 
can be calculated at birth. Thus, the GRS may help to identify individuals with a high genetic 475 
predisposition for gout, allowing for compensatory lifestyle choices to reduce the risk of gout. 476 
 477 
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High genetic correlations of serum urate with cardio-metabolic traits  478 
Serum urate is positively correlated with many cardio-metabolic risk factors and diseases32. We 479 
assessed genetic correlations between urate and 748 complex traits using cross-trait LD score 480 
regression (Methods). Serum urate levels were significantly (P < 6.6 x 10-5 = 0.05/748) 481 
genetically correlated with 214 complex traits and diseases (Supplementary Table 12). The 482 
highest positive genetic correlation (rg) was with gout (rg = 0.92, P = 3.3 x 10-70), followed by 483 
traits representing components of the metabolic syndrome such as HOMA-IR (rg = 0.49) and 484 
fasting insulin (rg = 0.45, Fig. 3). The largest negative correlations were observed with HDL 485 
cholesterol-related measurements (rg up to -0.46), and with estimated glomerular filtration rate 486 
(rg = -0.38 and -0.26 for cystatin C and creatinine-based estimated glomerular filtration rate 487 
(eGFR), respectively), consistent with the known role of the kidneys in urate excretion. Overall, 488 
the genetic correlations were consistent with observational associations from epidemiological 489 
studies32. 490 
 To examine whether these genetic correlations reflect causal relationships or pleiotropy, 491 
we applied a recently developed latent causal variable (LCV) model to estimate the genetic 492 
causality proportion (GCP) for seven commonly studied cardio-metabolic traits (Methods). As a 493 
positive control, we analyzed gout, confirming a genetically causal effect of urate on gout (GCP 494 
= 0.79; Supplementary Table 13), consistent with Mendelian randomization (MR) studies33,34. 495 
The seven cardio-metabolic traits showed a GCP range consistent with mostly or partially 496 
genetically causal effects on serum urate. The largest GCP estimates were observed for 497 
adiposity-related traits (e.g. GCP = -0.84 for waist circumference; Supplementary Table 13), 498 
where higher cell numbers should result in higher purine and consequently urate production. A 499 
bi-directional MR study reported a causal effect of adiposity on serum urate levels35. While the 500 
GCP and MR methods estimate different quantities to assess causality, the direction of effect 501 
can be compared and was consistent with a positive causal effect of obesity on serum urate. 502 
Smaller GCP estimates for HDL cholesterol levels (GCP < 0.5; Supplementary Table 13) on the 503 
other hand suggest the existence of a genetic process with a causal effect on both HDL 504 
cholesterol and serum urate, for example co-regulated metabolic processes in the liver. These 505 
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processes may explain a large fraction of heritability for cholesterol levels and a modest 506 
fraction for urate, a type of asymmetry expected to produce a partially genetically causal 507 
relationship consistent with the one observed. MR studies did not support a causal relationship 508 
between cholesterol levels and serum urate36. 509 
 510 
Enriched tissues and pathways  511 
To identify tissues and molecular mechanisms relevant for urate metabolism and handling, and 512 
to provide potential clues to the observed genetic correlations, we investigated which tissues, 513 
cell types and systems were significantly enriched for the expression of genes mapping into 514 
urate-associated loci (Methods). Based on all SNPs with P < 1 x 10-5, we identified significant 515 
enrichment (false discovery rate (FDR) < 0.01) for 19 physiological systems, three tissues, and 516 
two cell types (Supplementary Table 14). The strongest enrichment was observed for kidney (P 517 
= 9.5 x 10-9) and urinary tract (P = 9.9 x 10-9), consistent with the kidney’s prominent role in 518 
controlling urate levels. Additional significant enrichments were observed for endocrine and 519 
digestive systems, including liver, the major site of urate production. Interestingly, a novel 520 
significant enrichment was also observed in the musculoskeletal system, specifically for synovial 521 
membrane, joint capsule, and joints (Fig. 4a), the sites of gout attacks.  522 
We next tested for cell-type groups with evidence for enriched heritability based on cell-523 
type-specific functional genomic elements using stratified LD score regression (Methods). The 524 
strongest enrichment was observed for kidney (11.5-fold), followed by liver (5.39-fold; 525 
Supplementary Table 15).  526 
Lastly, we tested whether any gene sets were enriched for variants associated with 527 
urate at P < 10-5 (Methods). Significant enrichment (FDR < 0.01) was observed for 383 528 
reconstituted gene sets (Supplementary Table 16). Since many of these contained overlapping 529 
groups of genes, we used affinity propagation clustering to identify 57 meta gene sets 530 
(Methods and Supplementary Table 17), including a prominent group of inter-correlated gene 531 
sets related to kidney and liver development, morphology and function (Fig. 4b). Together, 532 
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these results underscore the prominent roles of the kidney and liver in regulating serum urate 533 
levels and implicate the kidney as a major target organ for lowering serum urate. 534 
 535 
Prioritization via fine-mapping, functional annotation, and gene expression 536 
We established a workflow that combined fine mapping of urate-associated loci with functional 537 
annotation and a systematic evaluation of tissue-specific differential gene expression to 538 
prioritize target SNPs and genes for translational research. 539 
Statistical fine-mapping prioritizes candidate SNPs. Statistical fine-mapping was 540 
performed starting from the 123 genome-wide significant loci identified in the EA-specific 541 
meta-analysis, because the workflow included methods that used LD estimates from an 542 
ancestry-matched reference panel (Methods)37. After LD-based combination into 99 larger 543 
genomic regions, stepwise model selection in each region identified 114 independent SNPs (r2 < 544 
0.01, Methods). Overall, 87 regions contained one independent SNP, ten contained two 545 
independent SNPs, the ABCG2 locus contained three and the SLC2A9 locus four independent 546 
SNPs (Supplementary Table 18). We computed 99% credible sets representing the smallest set 547 
of SNPs which collectively account for 99% posterior probability of containing the variant(s) 548 
driving the association signal (PPA)38. The 99% credible sets contained a median of 16 SNPs (Q1, 549 
Q3: 6, 57), and six of them only a single SNP, mapping in or near INSR, RBM8A, MPPED2, 550 
HNF4A, CPT1C, and SLC2A9 (Supplementary Table 18). Among 28 small credible sets (≤ 5 SNPs), 551 
several mapped in or near genes with an established role in urate handling such as SLC2A9, 552 
PDZK1, ABCG2, SLC22A11, and SLC16A920. These credible sets contain the most supported SNPs 553 
and greatly reduce the number of candidate variants for experimental follow-up.  554 
Credible set SNPs were annotated for their functional consequence and regulatory 555 
potential (Methods). Missense SNPs with PPA > 50% or belonging to small credible sets were 556 
identified in ABCG2, UNC5CL, HNF1A, HNF4A, CPS1, and GCKR (Fig. 5a and Supplementary 557 
Table 19). All missense SNPs except the one in GCKR had a CADD score > 15, supporting them 558 
as potentially deleterious. Indeed, functional effects have already been demonstrated 559 
experimentally for rs2231142 (Gln141Lys, r2 = 1 to the index SNP rs74904971) in ABCG2, 560 
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rs742493 (p.Arg432Gly) in UNC5CL, and rs1260326 (p.Leu446Pro) in GCKR (Table 1). Non-exonic 561 
variants with PAA > 90% and mapping into open chromatin in enriched tissues were identified 562 
in RBM8A, SLC2A9, INSR, HNF4A, PDZK1, NRG4, UNC5CL, and AAK1 (Methods, Supplementary 563 
Fig. 6 and Supplementary Table 19). When complemented by evidence of gene expression co-564 
localization, these SNPs may represent causal regulatory variants and highlight their potential 565 
effector genes.  566 
We compared our fine-mapping workflow (“Wakefield”), established in previous 567 
studies39,40, to an alternative approach implemented in FINEMAP (Methods)41. FINEMAP 568 
identified 152 credible sets (median of 7 SNPs). With respect to known causal variants in ABCG2 569 
(rs2231142), GCKR (rs1260326), HNF4A (rs1800961) and PDZK1 (rs1967017), the Wakefield 570 
approach identified the causal variants in ABCG2, GCKR, and HNF4A as credible set members, 571 
whereas FINEMAP found those in ABCG2 and HNF4A. A comparison of all SNPs mapping into 572 
small credible sets (≤ 5 SNPs) identified through both approaches found highly correlated 573 
posterior probabilities (Pearson correlation coefficient 0.86, Supplementary Table 19). 574 
Gene prioritization via gene expression co-localization analyses. The urate association 575 
signals were next tested for co-localization with expression quantitative trait loci (eQTL) in cis 576 
across three kidney tissue resources and 44 GTEx tissues (Methods). High posterior probability 577 
of co-localization (H4 ≥ 0.8, Methods) supports a trait-associated variant acting through gene 578 
expression in the tissue where co-localization is identified. We identified co-localization with 579 
the expression of 13 genes in kidney (Fig. 6), the organ with the strongest enrichment for urate-580 
associated variants. Whereas co-localization of some genes was only observed in kidney 581 
(SLC17A4, BICC1, UMOD, GALNTL5, NCOA7), others showed co-localization in several tissues 582 
(e.g., ARL6IP5). The direction of change in gene expression with higher urate levels could vary 583 
for the same gene across tissues. For instance, the allele associated with higher serum urate at 584 
SLC16A9 was associated with higher gene expression in kidney, consistent with a regulatory 585 
variant in a transporter mediating the reabsorption of urate. This same allele was associated 586 
with lower gene expression in other tissues such as aorta, pointing towards tissue-specific 587 
regulatory mechanisms42. Details of the 13 genes with evidence for co-localization with gene 588 
expression in kidney are summarized in Supplementary Table 20. Significant co-localizations 589 
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across all 47 tissues (Supplementary Fig. 7) revealed additional insights such as co-localization 590 
of the urate association signal with NFAT5 expression in subcutaneous adipose tissue, 591 
emphasizing its role in adipogenesis43, or PDZK1 expression in colon and ileum, important sites 592 
of urate excretion. 593 
Lastly, we investigated whether any trans-ethnic index SNPs or their proxies (r2 > 0.8) 594 
were reproducibly associated with gene expression in trans in several large eQTL studies 595 
(Supplementary Table 21 and Supplementary Note). We identified inter-chromosomal 596 
associations between five index SNPs and 16 transcripts that were enriched in the term 597 
“cardiovascular disease” based on the Human Disease Ontology database (Supplementary Note 598 
and Supplementary Table 22). 599 
 600 
HNF4A activates ABCG2 transcription and HNF4A p.Thr139Ile is a functional variant 601 
The gene and variant prioritization workflow was validated using the identified candidates 602 
HNF1A and HNF4A. Co-regulation of target genes by these transcriptional master regulators in 603 
kidney proximal tubule and liver could potentially explain observed genetic correlations44. 604 
  We first tested whether HNF1A and HNF4A affect transcription of ABCG2, which 605 
encodes for a major human urate transporter and represented the locus with the highest gout 606 
risk in our screen. The ABCG2 promoter region contains several predicted HNF1A and HNF4A 607 
binding sites (Fig. 5b). A luciferase reporter assay in the human embryonic kidney cell line HEK 608 
293 was used to assess transactivation of the human ABCG2 promoter by HNF4A and HNF1A 609 
proteins (Methods and Supplementary Fig. 8a). Co-expression of HNF4A significantly increased 610 
the ABCG2 promoter-driven luciferase activity in a transfection dose- and HNF4A protein 611 
abundance-dependent manner (Fig. 5c and Supplementary Fig. 8b). No increase of luciferase 612 
activity occurred with the negative-control vector devoid of the ABCG2 promoter 613 
(Supplementary Fig. 8d,e). Results for HNF1A indicated that the observed association with 614 
serum urate is unlikely to occur via activation of ABCG2 in kidney cells (Fig. 5c), but HNF1A has 615 
been reported to activate transcription of PDZK1, which encodes a regulatory protein for 616 
several other renal urate transporters45,46 also identified in this study. 617 
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Next, we tested the functional relevance of the prioritized p.Thr139Ile allele in HNF4A 618 
(NM_178849.2, isoform 1, Methods). Its location within the hinge/DNA binding domain (Fig. 5d 619 
and Supplementary Fig. 8f) supports potentially altered interactions with targeted promoter 620 
regions. The isoleucine substitution at position 139 significantly increased the transactivation of 621 
the ABCG2 promoter as compared to the wild-type threonine (Fig. 5e), without altering HNF4A 622 
protein abundance (Supplementary Fig. 8c). Thus, HNF4A can activate ABCG2 transcription in a 623 
kidney cell line, and HNFA4 p.Thr139Ile is a functional variant. Increased activation of the urate 624 
excretory protein ABCG2 by the allele encoding the isoleucine residue should result in lower 625 
serum urate levels, consistent with the observed negative association in our GWAS.  626 
 627 
 628 
Discussion  629 
This trans-ethnic GWAS meta-analysis of serum urate based on 457,690 individuals represents a 630 
four-fold increase in sample size over previous studies21,22,47 and identified 183 urate-associated 631 
loci, 147 of which are novel. A genetic urate risk score led to significant improvements of gout 632 
risk prediction among 334,880 UKBB participants: 3.5% had a risk of gout comparable to a 633 
Mendelian disease effect size. Genetic correlation and causality analyses confirmed the causal 634 
effect of urate on gout, and were consistent with transcriptional co-regulation as a source of 635 
pleiotropy in the widespread genetic correlations between serum urate and cardio-metabolic 636 
traits. Tissue and cell type-specific enrichment analyses supported kidney and liver, the sites of 637 
urate excretion and generation, as key target tissues. Comprehensive fine-mapping and co-638 
localization analyses with gene expression across 47 tissues delivered an extensive list of target 639 
genes and SNPs for follow-up studies, of which we experimentally confirmed HNF4A 640 
p.Thr139Ile as a functional allele involved in transcriptional regulation of urate homeostasis.  641 
Major challenges of GWAS are to pinpoint causal genes and variants, and to provide 642 
actionable insights into disease-relevant mechanisms. This study developed a comprehensive 643 
resource of urate-related candidate SNPs, genes, tissues and pathways that will enable a wide 644 
range of follow-up studies. Out of the many novel and biologically plausible findings, we 645 
highlight two instances in which co-localization analyses provided new insights. First, co-646 
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localization helped to prioritize genes in association peaks that previous GWAS could not 647 
resolve. For example, the locus at chromosome 6p22.2 contains genes encoding for four 648 
members of the SLC17 transporter family (SLC17A1-SLC17A4). Systematic testing of co-649 
localization across genes and tissues identified evidence only for SLC17A4 in kidney, with higher 650 
expression associated with higher serum urate. Previous experimental studies have implicated 651 
SLC17A4 as a urate exporter in intestine48, and our data support its yet unappreciated role in 652 
renal urate transport. Second, co-localization with MUC1, BICC1 and UMOD expression in 653 
kidney suggests a shared biological mechanism. Rare mutations in all three genes underlie 654 
monogenic cystic kidney diseases49-51.  655 
Another noteworthy finding is the significant genetic correlations with many cardio-656 
metabolic traits, consistent with observational associations52. Many of these traits are 657 
influenced by liver metabolism. The estimated genetic causality proportions supported their 658 
genetic correlations to be partly driven by overlapping or co-regulated metabolic pathways and 659 
not only by a fully causal effect of e.g. cholesterol or insulin levels on urate. Likewise, significant 660 
genetic correlations with kidney-related traits such as eGFR may reflect shared regulatory 661 
processes in the kidney. The observed pleiotropic effects of many urate-associated variants 662 
could thus be the potential manifestation of co-regulation of processes that occur within and 663 
across tissues relevant to the implicated traits, a mechanism likely to be prevailing in metabolic 664 
but also other traits.  665 
In the kidney, nuclear HNF4A is exclusively detected in the proximal tubule53, where it 666 
has been reported to regulate the expression of SLC2A9 isoform 154 and PDZK155. Kidney-667 
specific deletion of Hnf4a in mice phenocopies Fanconi renotubular syndrome56. Transcriptomic 668 
analyses support HNF4A to drive a proximal tubule signature cluster of 221 co-expressed genes, 669 
including many candidate genes for urate metabolism and transport53. In addition to HNF4A, 670 
HNF4G, and HNF1A, ten genes in this cluster also map into urate-associated loci we identified 671 
(A1CF, CUBN, LRP2, PDZK1, SERPINF2, SLC2A9, SLC16A9, SLC17A1, SLC22A12 and SLC47A1). In 672 
addition, our study establishes that HNF4A can trans-activate transcription of ABCG2 in a kidney 673 
cell line, the key urate secretory transporter in gut and kidney epithelium57. The genetic variant 674 
encoding the p.Thr139Ile substitution is located in a region of the HNF4A protein harboring 675 
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many causative mutations for monogenic maturity onset diabetes of the young (MODY type 676 
1)58. Yet, unlike the severe MODY1 missense mutations p.Arg127Trp, p.Asp126Tyr, 677 
p.Arg125Trp,59 p.Thr139Ile has not been reported to cause MODY1. Instead, it has been 678 
reported to increase the risk of type 2 diabetes, possibly through a liver-specific loss of HNF4A 679 
phosphorylation at p.Thr139, and to associate with HDL-cholesterol levels58,60.  These data point 680 
to additional complexities when interpreting pleiotropic effects, because there may be several 681 
tissue-specific mechanisms by which genetic variants in transcriptional regulators influence 682 
metabolic pathways and urate homeostasis. 683 
Some limitations warrant mention. The numbers of individuals of ancestries other than 684 
European or East Asian were small, and the generalizability of the gout prediction models 685 
should be assessed in future independent studies of non-European ancestry. Focusing on SNPs 686 
present in the majority of studies emphasizes those that may be of greatest importance globally 687 
over population-specific variants. General limitations of the field include that statistical fine-688 
mapping approaches based on meta-analysis summary statistics cannot clearly prioritize 689 
functional variants in regions of tight LD, and that they are influenced by the availability and 690 
imputation quality of SNPs in the contributing studies. Only few regulatory maps from 691 
important target tissues such as synovial membrane and kidney are available, but we were able 692 
to evaluate differential gene expression in three kidney datasets. Generating additional 693 
regulatory and expression datasets across disease states, developmental stages and additional 694 
cell types in kidney and other metabolically active organs constitutes an important future 695 
research avenue. Lastly, a large independent sample for adequately powered replication testing 696 
was unavailable and represents a future endeavor. However, high correlations between genetic 697 
effects on serum urate and gout even for SNPs with the weakest significant urate associations 698 
as well as no indication of significant heterogeneity reduce concerns about false positives.  699 
In summary, this large-scale study generated an atlas of candidate SNPs, genes, tissues 700 
and pathways involved in urate metabolism and its shared regulation with multiple cardio-701 
metabolic traits that will enable a wide range of follow-up studies. 702 
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Figure Legends 998 
Figure 1 | Trans-ethnic GWAS meta-analysis identifies 183 loci associated with serum urate. 999 
Outer ring: Dot size represents the genetic effect size of the index SNP at each labeled locus on 1000 
serum urate. Blue band: –log10(two-sided meta-analysis P-value) for association with serum 1001 
urate (n = 457,690), by chromosomal position (GRCh37 (hg19) reference build). Red line 1002 
indicates genome-wide significance (P = 5 × 10-8). Blue gene labels indicate novel loci, gray 1003 
labels loci reported in previous GWAS of serum urate. Green band: –log10(two-sided meta-1004 
analysis P-value) for association with gout (n = 763,813), by chromosomal position. Red line 1005 
indicates genome-wide significance (P = 5 × 10-8). Inner band: Dots represent index SNPs with 1006 
significant heterogeneity and are color-coded according to its source: green for ancestry-1007 
related heterogeneity (Panc-het < 2.7 × 10-4 (0.05/183)), red for residual heterogeneity (Pres-het < 1008 
2.7 × 10-4), and yellow for both (Panc-het and Pres-het < 2.7 × 10-4). Loci are labeled with the gene 1009 
closest to the index SNP. Panc-het and Pres-het were generated by MR-MEGA (Methods). 1010 
 1011 
Figure 2 | A genetic risk score (GRS) for serum urate improves gout risk prediction. a, 1012 
Histogram of the urate GRS among 334,880 European ancestry participants of the UK Biobank. 1013 
The y-axes show the number of individuals (left) and the prevalence of gout (right), the x-axis 1014 
shows categories of the urate GRS. The units on the x-axis represent genetically predicted 1015 
serum urate levels (mg/dl) compared to individuals without any urate-increasing alleles. b,  1016 
Age- and sex-adjusted odds ratio of gout (y-axis) by GRS category (x-axis) among 334,880 1017 
European-ancestry participants of the UK Biobank, comparing each category to the most 1018 
prevalent category (4.74 < GRS ≤ 5.02) with error bars representing 95% confidence intervals; * 1019 
denotes logistic regression two-sided P-value < 0.05, ** denotes P < 5 x 10-10, and *** P < 5 x 1020 
10-100. c, Comparison of the receiver operating characteristic (ROC) curves of different 1021 
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prediction models of gout: genetic (GRS only; red), demographic (age + sex; green), and 1022 
combined (GRS + age + sex; blue). y-axis: sensitivity, x-axis: specificity. At the optimal cut points 1023 
determined by the maximum of the Youden’s index, the sensitivity of the combined model was 1024 
84% and specificity was 68%.  1025 
 1026 
Figure 3 | Serum urate shows widespread genetic correlations with cardio-metabolic risk 1027 
factors and diseases. The Circos plot shows significant genome-wide genetic correlations 1028 
between serum urate and 214 complex traits or diseases (genetic correlation P < 6.6 x 10-5 = 1029 
0.05/748 traits tested), with bar height proportional to the genetic correlation coefficient (rg) 1030 
estimate for each trait and coloring according to its direction (dark blue, rg > 0; light blue, rg < 0). 1031 
Traits and diseases are labeled on the outside of the plot and grouped into nine different 1032 
categories. Each category is color-coded (inner ring, inset). The greatest genetic correlation was 1033 
observed with gout (rg = 0.92, P = 3.3 x 10-70). Genetic correlations with multiple cardio-1034 
metabolic risk factors and diseases reflect their known directions from observational studies. 1035 
The serum urate association statistics for estimating genetic correlations were from the 1036 
European-ancestry meta-analysis (n = 288,649).  1037 
 1038 
Figure 4 | Genes expressed in urate-associated loci are enriched in kidney tissue and 1039 
pathways. a, Grouped physiological systems (x-axis) that were tested individually for 1040 
enrichment of expression of genes in urate-associated loci among European-ancestry 1041 
individuals (n = 288,649) using DEPICT are shown as a bar plot, with the –log10(enrichment P-1042 
value) on the y-axis. Significantly enriched systems are labeled and highlighted in blue 1043 
(enrichment false discovery rate (FDR) < 0.01). b, Correlated (r > 0.2) meta-gene sets that were 1044 
strongly enriched (enrichment FDR < 0.01) for genes mapping into urate-associated loci among 1045 
European-ancestry individuals (n = 288,649). Thickness of the edges represents the magnitude 1046 
of the correlation coefficient, node size, color and intensity represent the number of clustered 1047 
gene sets, gene set origin, and enrichment P-value, respectively. 1048 
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 1049 
Figure 5 | Prioritization of p.Thr139Ile at HNF4A and functional study of HNF4A regulation of 1050 
ABCG2 transcription. a, Graph shows credible set size (x-axis) against the posterior probability 1051 
of association (PPA; y-axis) for each of 1,453 SNPs with PPA > 1% in 114 99% credible sets. 1052 
Triangles mark missense SNPs, with size proportional to their Combined Annotation Dependent 1053 
Depletion (CADD) score. Blue triangles indicate missense variants mapping into small (≤ 5 SNPs) 1054 
credible sets or with high PPA (≥ 50%). b, Predicted HNF1A or HNF4A binding sites in the 1055 
promoter region of ABCG2 using LASAGNA 2.0, the consensus affinity sequence, and the P-1056 
value of likely matches based on nucleotide position within a consensus transcription factor 1057 
binding site (Methods). c, Relative luciferase activity and transactivation of ABCG2 promoter in 1058 
cells transfected with variable amount of HNF1A or HNF4A constructs (mean (line) ± s.e.m. 1059 
(whiskers), n = 3 independent experiments, P-values calculated with ordinary one-way ANOVA 1060 
with Tukey’s multiple comparison test). d, Position of p.Thr139Ile (T139I) in DNA binding 1061 
domain/hinge region within HNF4A homodimer structure (PDB 4IQR). e, Relative luciferase 1062 
activity and transactivation of ABCG2 promoter in cells transfected with variable amount of 1063 
constructs (ng’s of transfected DNA) of wild-type HNF4A (threonine) or isoleucine at position 1064 
139 (± s.e.m., n = 3 independent experiments, P-values calculated with ordinary one-way 1065 
ANOVA with Tukey’s multiple comparison test). 1066 
 1067 
Figure 6 | Co-localization of urate-association signals with gene expression in cis in kidney 1068 
tissues. Serum urate association signals identified among European ancestry individuals (n = 1069 
288,649) were tested for co-localization with all eQTLs where the eQTL cis-window overlapped 1070 
(±100 kb) the index SNP. Genes with ≥1 positive co-localization (posterior probability of one 1071 
common causal variant, H4, ≥ 0.80) in a kidney tissue are illustrated with the respective index 1072 
SNP and transcript (y-axis). Co-localizations across all tissues (x-axis) are illustrated as dots, 1073 
where the size of the dots indicates the posterior probability of the co-localization. Negative co-1074 
localizations (posterior probability of H4 < 0.80) are marked in gray, while the positive co-1075 
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localizations are color-coded relative to the change in expression with a color gradient as 1076 
indicated in the legend.1077 
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 1078 
Table 1 | Genes implicated as causal via identification of missense variants with high probability of driving the urate association 1079 
signal. Genes are included if they contain a missense variant with posterior probability of association of >50% or mapping into a 1080 
small credible set (≤5 SNPs). 1081 
Gene SNP #SNPs 
in set  
SNP 
PP Consequence 
CADD DHS Gout meta-
analysis P-
value (EA) 
Brief summary of literature and gene function 
ABCG2 rs2231142 4 0.41 p.Gln141Lys 
(NP_004818.2) 
18.2 ENCODE 
epithelial 
1.21E-290 Encodes a xenobiotic and high-capacity urate membrane transporter expressed in kidney, liver and gut. Causal 
variants have been reported for gout susceptibility (#138900) and the Junior Jr(a-) blood group phenotype 
(#614490). The locus was first identified in association with serum urate through GWAS (PMID:18834626) and 
confirmed in many studies since. The common causal variant Q141K has been experimentally confirmed 
(PMID:19506252) as a partial loss of function.  
UNC5CL rs742493 4 0.95 p.Arg432Gly 
(NP_775832.2) 
 
(within Death 
domain) 
21.0 ENCODE 
epithelial 
2.73E-01 Encodes for the death-domain-containing Unc-5 Family C-Terminal-Like membrane-bound protein. Suggested 
as a candidate gene for mucosal diseases, with a role in epithelial inflammation and immunity 
(PMID:22158417). Experiments using human HEK293 cells showed that UNC5CL can transduce pro-
inflammatory programs via activation of NF-κB, with the 432Gly variant less potent to do so than the 432Arg 
one (PMID:22158417). 
HNF1A rs1800574 2 0.92 p.Ala98Val 
(NP_000536.5) 
23.4  1.83E-02 Encodes a transcription factor with strong expression in liver, guts and kidney. Rare mutations cause 
autosomal-dominant MODY type III (#600496). Locus found in GWAS of T2D (PMID:22325160) and blood urea 
nitrogen (PMID:29403010). Together with HNF4-alpha, it was first recognized as master regulator of 
hepatocyte and islet transcription. Knockout mice show proximal tubular dysfunction (Fanconi syndrome). 
HNF1A enhanced promoter activity of PDZK1, URAT1, NPT4 and OAT4 in human renal proximal tubule cell-
based assays (PMID:28724612), supporting a role in the coordinated expression of components of the urate 
“transportosome”.  
HNF4A rs1800961 1 1.00 p.Thr139Ile 
(NP_000448.3) 
24.7 ENCODE 
pancreas 
7.43E-03 Encodes another nuclear receptor and transcription factor that controls expression of many genes, including 
HNF1A and other overlapping target genes. Rare mutations cause autosomal-dominant MODY type I 
(#125850) and autosomal-dominant renal Fanconi syndrome 4 (# 616026). Shown to regulate expression of 
SLC2A9 and other members of the urate "transportosome" in cell-based assays (PMID 25209865, 
PMID:30124855). The GWAS locus has been reported for multiple cardio-metabolic traits and T2D 
(PMID:21874001). 
CPS1 rs1047891 84 0.84 p.Thr1412Asn 
(NP_001116105.1) 
22.1  5.66E-02 Encodes mitochondrial carbamoyl phosphate synthetase I, which catalyzes the first committed step of the 
urea cycle by synthesizing carbamoyl phosphate from ammonia, bicarbonate, and 2 molecules of ATP. Rare 
mutations cause autosomal-recessive carbamoylphosphate synthetase I deficiency (#237300). In addition to 
hyperammonemia, this disease features increased synthesis of glutamine, a precursor of purines. Elevated 
uric acid excretion has been reported in patients with hyperammonemia (PMID:6771064). GWAS locus for 
eGFR (PMID:26831199), homocysteine (PMID:23824729), urinary glycine concentrations (PMID: 26352407). 
GCKR rs1260326 2 0.67 p.Leu446Pro 
(NP_001477.2) 
0.1 ENCODE 
kidney 
4.09E-41 Encodes a regulatory protein prominently expressed in the liver that inhibits glucokinase. Identified in 
previous GWAS of urate (PMID:23263486) and multiple other cardio-metabolic traits. The 446L protein was 
shown to be less activated than 446Pro by physiological concentrations of fructose-6-phosphate, leading to 
reduced glucokinase inhibitory ability (PMID:19643913). 
Abbreviation: PP, posterior probability; DHS, DNase-I hypersensitivity site; CADD, Combined Annotation Dependent Depletion phred score; EA, European ancestry. 1082 
Gout meta-analysis P-values were two-sided (n = 763,813). Posterior probabilities were estimated from statistical fine-mapping using the Wakefield approach (Methods).1083 
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Online Methods 1084 
  1085 
Phenotype definition, genotyping and imputation in participating studies  1086 
The primary study outcome was serum urate in mg/dl. The laboratory methods for measuring 1087 
serum urate in each study are reported in Supplementary Table 1. Prevalent gout was analyzed 1088 
as a secondary outcome to examine whether urate-associated SNPs conferred gout risk. Gout 1089 
cases were ascertained based on self-report, intake of urate-lowering medications, or 1090 
International Statistical Classification of Diseases and Related Health Problems (ICD) codes for 1091 
gout (Supplementary Table 1). The participants of all studies provided written informed 1092 
consent. Each study had its research protocol approved by the corresponding local ethics 1093 
committee.  1094 
 Each study performed genotyping separately and imputed the genotypes to reference 1095 
panels of the Haplotype Reference Consortium (HRC) version 1.161, 1000 Genomes Project 1096 
(1000G) phase 3 v5 ALL, or the 1000G phase 1 v3 ALL62. Study-specific quality filters, and 1097 
software used for phasing and imputation are provided in Supplementary Table 2 and the 1098 
Supplementary Note. Variants were annotated using NCBI b37 (hg19).  1099 
 1100 
Study-specific association analysis 1101 
Phenotype generation was standardized across studies using a common script, and study-1102 
specific association analyses followed a centrally developed analysis plan. GWAS summary 1103 
statistics were checked centrally using GWAtoolbox63 and custom scripts (Supplementary 1104 
Note). Each study performed ancestry-specific association analysis of serum urate by 1105 
generating age- and sex-adjusted residuals of serum urate and regressing the residuals on SNP 1106 
dosage levels, adjusting for study-specific covariates such as study centers and genetic principal 1107 
components, assuming an additive genetic model. Gout was analyzed as a binary outcome 1108 
adjusting for age, sex, genetic principal components, and study-specific covariates. Software 1109 
used for these regression analyses were EPACTS (q.emmax for family based studies and q.linear 1110 
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otherwise; https://genome.sph.umich.edu/wiki/EPACTS), SNPTest64, RegScan65, RVTEST66, 1111 
PLINK 1.9067, Probabel68, GWAF69, GEMMA70, mach2qtl71 and R. Family-based studies used 1112 
methods that accounted for relatedness. 1113 
 1114 
Trans-ethnic, ancestry-specific, and sex-stratified meta-analyses 1115 
GWAS results from each study were pre-filtered to retain bi-allelic SNPs with imputation quality 1116 
score > 0.6 and minor allele count (MAC) > 10 before inclusion into meta-analysis. Fixed effects 1117 
inverse-variance weighted meta-analysis was performed using METAL72 with modifications to 1118 
output higher precision (six decimal places). Genomic control was applied for each study. The 1119 
genomic inflation factor λGC73 was calculated to assess inflation of the test statistics. For each 1120 
meta-analysis result (trans-ethnic, ancestry-specific, and sex-specific), we excluded SNPs that 1121 
were present in <50% of the studies and with a total MAC < 400. For ancestry-specific meta-1122 
analysis, we additionally excluded SNPs with a heterogeneity I²-statistic74 > 95%. Genome-wide 1123 
significance was defined as P-value < 5 x 10-8. The LD score regression intercept was calculated 1124 
to assess the evidence for associations driven by population structure75. For downstream 1125 
characterization, 8,249,849 and 8,217,339 autosomal SNPs were retained in the trans-ethnic 1126 
and European ancestry meta-analysis, respectively. Ancestry-specific meta-analyses were 1127 
conducted for European ancestry (EA), African Americans (AA), East Asian (EAS) ancestry, and 1128 
South Asian (SA) ancestry using the same methods and variant filters as the trans-ethnic meta-1129 
analysis. 1130 
Secondary meta-analyses were performed separately in men and women, using the 1131 
same analytical approaches. To test for significant difference of association between males and 1132 
females, we used a two-sample t-test: 1133 
 	ݐ = 	 ఉಾି	ఉಷ
ටௌாಾమା	ௌாಷమ
 1134 
where ߚM and ߚF were beta coefficients in males and females, respectively, and SEM and SEF 1135 
were the standard errors among males and females, respectively.  1136 
 1137 
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 1138 
Initial determination and annotation of genome-wide significant loci 1139 
For each meta-analysis result, the SNP with the lowest P-value per chromosome was selected 1140 
as an initial index SNP, and along with the +/- 500 kb surrounding was defined as one 1-Mb 1141 
locus. This procedure was repeated with the SNP with the lowest P-value not yet assigned to a 1142 
locus, until no genome-wide significant SNPs outside 1-Mb loci remained. To visualize loci, the 1143 
genomic region +/- 500 kb around each index SNP was plotted and can contain two index SNPs 1144 
when index SNPs were > 500kb but < 1 Mb apart. An ancestry-specific locus was defined as a 1145 
genome-wide significant locus in an ancestry-specific meta-analysis of which the index SNP did 1146 
not map into within the ±500 kb intervals of any genome-wide significant loci in the trans-1147 
ethnic meta-analysis. Index SNPs were annotated using its position and the nearest gene based 1148 
on hg19, RefSeq genes, and dbSNP147 downloaded from 1149 
ftp://hgdownload.soe.ucsc.edu/mysql/hg19/ on 23 March 2017. 1150 
 1151 
Proportion of phenotypic variance explained and estimated heritability 1152 
The proportion of phenotypic variance explained by index SNPs was calculated as the sum of 1153 
the variance explained by each index SNP based on this formula: ߚଶ ቀଶ௣ሺଵି௣ሻ௩௔௥ ቁ, where ߚ is the 1154 
beta coefficient and ݌ is the MAF of the SNP, and ݒܽݎ is the phenotypic variance. For this study, 1155 
we used the variance of the age- and sex-adjusted residuals of serum urate in EA participants of 1156 
the ARIC study as the estimate of the phenotypic variance (variance = 1.767).  1157 
Genetic heritability of age- and sex-adjusted urate levels was estimated using the R 1158 
package ‘MCMCglmm’76 in the Cooperative Health Research In South Tyrol (CHRIS) study77, a 1159 
participating EA study with 4,373 individuals split into 186 up-to-five generation pedigrees78. 1160 
Genetic heritability was estimated overall, after accounting for the index SNPs of the three 1161 
major urate loci (SLC2A9, ABCG2, and SLC22A12), and after accounting for the index SNPs of all 1162 
genome-wide significant loci for both the trans-ethnic and EA-specific meta-analyses. Estimates 1163 
were obtained by running 1,000,000 MCMC iterations (burn in = 500,000) based on previously 1164 
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described settings78. The difference between the overall heritability and the heritability 1165 
excluding the index SNPs represents the heritability explained by the identified loci. 1166 
 1167 
Trans-ethnic meta-regression  1168 
Prior to conducting trans-ethnic meta-regression, we applied the same study-specific SNP filters 1169 
as those applied to the fixed effects trans-ethnic meta-analysis (imputation quality score > 0.6 1170 
and MAC > 10). An additional filter for MAF > 0.0025 was also applied to reduce the influence of 1171 
rare SNPs that passed the MAC filter in very large studies. Trans-ethnic meta-regression was 1172 
conducted using the MR-MEGA software package79, which models ancestry-associated 1173 
heterogeneity in the allelic effect as a function of principal components (PCs) generated from a 1174 
matrix of mean pairwise allele frequency differences between studies. Three principal 1175 
components generated from a matrix of mean pairwise allele frequency differences between 1176 
studies were sufficient to separate the self-reported ancestry groups. Due to software 1177 
requirements, the minimum number of cohorts for each SNP had to be greater than the 1178 
number of PCs plus two, resulting in the exclusion of SNPs present in five or fewer cohorts. In 1179 
addition to genome-wide SNP associations with urate, MR-MEGA reports ancestry-associated 1180 
(Panc-het) and residual heterogeneity (Pres-het). Index SNPs from the fixed effects meta-analysis 1181 
with Panc-het < 2.7 x 10-4 (0.05/183) in MR-MEGA were considered to have significant ancestry-1182 
associated heterogeneity.  1183 
 1184 
Effect of urate-associated index SNPs on gout and risk prediction for gout 1185 
To evaluate the association of the trans-ethnic urate-associated index SNPs with gout, we 1186 
conducted a trans-ethnic meta-analysis of gout with the same study-specific filtering criteria as 1187 
for the urate trans-ethnic meta-analysis.  1188 
 The association between a genetic urate risk score constructed from the 114 1189 
independent serum urate-associated SNPs identified among European individuals (see fine-1190 
mapping section below) and gout was assessed in a large, independent sample from the UKBB 1191 
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(Projects 19655 and 20272)80. We selected 334,880 unrelated individuals (pairwise kinship 1192 
coefficient < 0.0313) of White British ancestry with sex chromosome euploidy and concordance 1193 
of phenotypic and genotypic sex, including 4,908 with gout identified by self-report at the 1194 
inclusion visit. Individuals with an ICD10 for gout (M10) in hospital admissions who did not self-1195 
report gout were excluded from the analysis. A genetic risk score (GRS) was constructed as the 1196 
sum of the imputed dosage of the allele associated with higher urate levels (“risk alleles”) over 1197 
all SNPs, multiplied by the genetic effect of the risk allele on serum urate levels. The GRS 1198 
distribution was divided into ten evenly spaced categories, and individuals assigned to a 1199 
category based on their GRS. The category with the lowest GRS did not contain any gout cases 1200 
and so was combined with its adjacent category. Gout status was regressed on GRS category in 1201 
a logistic model, including age and sex as covariates, with the category containing the largest 1202 
number of individuals (genetically predicted mean urate levels 4.74-5.02 mg/dl higher 1203 
compared to individuals without any urate-increasing alleles) as the reference group. 1204 
The performance of the GRS for risk prediction of gout was first evaluated in a randomly 1205 
selected model development sample comprising 90% of the participants to obtain precise 1206 
estimates, and tested in a validation sample of the remaining 10%. Logistic regression was used 1207 
to regress gout on the GRS alone (genetic model), age and sex (demographic model) and GRS 1208 
with age and sex (combined model) in the model development sample. Each of these models 1209 
was then used to predict gout status in the validation sample. Model performance was assessed 1210 
by comparing predicted and true gout status using Area Under the Curve (AUC) in a Receiver 1211 
Operating Characteristic (ROC) curve. A cutoff of the ROC curve to report sensitivity and 1212 
specificity of a combined GRS-based diagnostic test was determined by the maximum of the 1213 
Youden's index (sensitivity + specificity - 1). Ten-fold cross-validation of the models was 1214 
performed by randomly dividing the UKBB sample into ten equally sized groups. Each group in 1215 
turn was used as the validation sample for the estimates developed on the remaining data. The 1216 
AUC the ROC curve was calculated for each of the three models for all ten validation samples, 1217 
and the means and standard deviations are reported. 1218 
 1219 
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Genetic correlation 1220 
To assess the genetic correlation between serum urate and other traits in EA, we conducted 1221 
cross-trait LD score regression81 using LD Hub82 with the EA-specific urate meta-analysis results 1222 
as input. Genetic correlation estimates with 746 traits were obtained from LD Hub, excluding 1223 
two previous serum urate GWAS results. For presentation, the 212 significantly correlated traits 1224 
(P < 6.7x10-5 = 0.05/746) were grouped into 9 categories based on the trait names and labels 1225 
and presented in a circos plot. 1226 
 To determine whether observed genetic correlations between serum urate and cardio-1227 
metabolic traits are likely to represent causal relationships, we used the recently developed 1228 
latent causal variable (LCV) method to estimate the genetic causality proportion (GCP) between 1229 
serum urate and another trait83. Compared to MR, the LCV method produces fewer false 1230 
positive results in the setting of high genetic correlation and large sample sizes, a situation 1231 
applicable to our analysis83. The GCP describes what proportion of the genetic component of 1232 
one trait also affects the other trait; a positive GCP value indicates that a proportion of the 1233 
genetic component of urate affects the other trait, and vice versa for a negative GCP value. LCV 1234 
produces posterior mean and standard deviation estimates of the GCP using mixed fourth 1235 
moments of the bivariate effect size distribution, based on GWAS summary statistics and LD 1236 
scores. When using summary statistics of cardio-metabolic traits generated from the UKBB, we 1237 
assumed non-overlapping populations, and overlapping populations otherwise. We selected six 1238 
unique continuous cardio-metabolic traits commonly examined in epidemiological studies with 1239 
high genetic correlation with serum urate (|rg| > 0.35). We additionally included gout as a 1240 
positive control and creatinine-based glomerular filtration rate. EA-specific GWAS summary 1241 
statistics were used as input to match the ancestry of the LD scores used with the method 1242 
(https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2).  1243 
 1244 
Functional enrichment 1245 
To assess gene-set and tissue enrichment, we used the Data-Driven Expression Prioritized 1246 
Integration for Complex Traits analysis (DEPICT) version 1 release 19484, which performs gene 1247 
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set enrichment analysis by testing whether genes in 14,461 reconstituted gene sets were 1248 
enriched for urate-associated SNPs (P-values < 1 x 10-5) from the trans-ethnic meta-analysis 1249 
results. Affinity propagation clustering (APC)85, implemented in the R package ‘APCluster’86, was 1250 
applied to all urate-associated reconstituted gene sets with false discovery rates (FDR)-1251 
corrected enrichment P-value < 0.01 to cluster gene sets containing similar combinations of 1252 
genes. More details on the methods of DEPICT and APC are provided in the Supplementary 1253 
Note. The methods for using stratified LD score regression81 based on cell type–specific 1254 
genomic annotations to identify cell type and tissue-specific enrichments of serum urate 1255 
heritability are reported in the Supplementary Note.  1256 
 1257 
Statistical fine-mapping of genome-wide significant loci in European ancestry 1258 
Statistical fine-mapping to identify potentially causal variants was performed for the genome-1259 
wide significant loci from the EA-specific meta-analysis. LD was estimated based on 16,969,363 1260 
SNPs from 13,558 unrelated UKBB participants after quality control (Supplementary Note). The 1261 
analyses were based on a previously described workflow39,40,87 using GCTA (cojo-slct option) to 1262 
identify independent index SNPs in each region, followed by using GCTA (cojo-cond option) to 1263 
obtain conditional beta and standard errors for regions with >1 independent signal. Next, 1264 
approximate Bayes factors (ABF) were calculated using the Wakefield’s formula38, as 1265 
implemented in the R package ’gtx’ version 2.0.1 (https://github.com/tobyjohnson/gtx). The 1266 
posterior probability for a variant being the driver of the association signal was calculated as 1267 
the ABF of the variant divided by the sum of the ABF in the region. The 99% credible sets of a 1268 
region is derived by summing the posterior probabilities in descending order until the 1269 
cumulative posterior probability was > 99%. We prioritized variants in credible sets containing ≤ 1270 
5 SNPs or SNPs with posterior probabilities > 0.5. More details on statistical fine-mapping are 1271 
provided in the Supplementary Note. 1272 
  1273 
Annotation of the variants in the credible sets 1274 
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We annotated SNPs in the credible sets for their exonic effect, Combined Annotation 1275 
Dependent Depletion (CADD) score, and mapping into DNaseI-hypersensitive sites (DHS) from 1276 
the Encyclopedia of DNA Elements (ENCODE) and Roadmap Epigenomics Consortium 1277 
projects88,89. The exonic effect and CADD score were obtained using SNiPA v3.2 (March 2017)90. 1278 
SNiPA presented the CADD score as PHRED-like transformation of the C score, which was based 1279 
on CADD release v1.3 downloaded from http://cadd.gs.washington.edu/download. A CADD 1280 
score of 15 is used to distinguish potentially deleterious variants from background noise in 1281 
clinical genetics, and represents the median value of all non-synonymous variants in CADD 1282 
v1.091,92. As opposed to posterior probabilities of causing the association signal, CADD scores 1283 
represent an integrative measure of predicted deleteriousness based on an ensemble of variant 1284 
annotations derived by contrasting common variants that survived natural selection with 1285 
simulated mutations. Based on known pathogenic variants in the ClinVar database, the 1286 
performance of the CADD score had an AUC of 0.8893.  1287 
 1288 
Co-localization analysis of cis-eQTL and urate-associated loci 1289 
Co-localization analysis of urate-associated loci with gene expression was conducted using EA 1290 
meta-analysis results, cis-eQTL results from micro-dissected human glomerular and tubulo-1291 
interstitial kidney portions from 187 individuals in the NEPTUNE study94, as well as from 44 1292 
tissues in the GTEx Project version 6p release95. For each urate locus, we identified all 1293 
transcripts and all tissue-transcript pairs with reported eQTLs within ±100 kb of each GWAS 1294 
index SNP. The region for each co-localization test was defined as the eQTL cis window in the 1295 
underlying studies94,95. We used the default parameters and prior definitions set in the 1296 
‘coloc.fast’ function from the R package ‘gtx’ (https://github.com/tobyjohnson/gtx), which is an 1297 
adapted implementation of Giambartolomei’s co-localization method24. Evidence for co-1298 
localization was defined as H4 ≥ 0.8, which represents the posterior probability that the 1299 
association with serum urate and gene expression is due to the same underlying variant. In 1300 
addition, co-localization of urate-associated loci was also performed with gene expression 1301 
quantified using RNA sequencing of the healthy tissue portion of 99 kidney cortex samples from 1302 
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the Cancer Genome Atlas (TCGA)96. First, all transcripts that shared eQTL variants with urate 1303 
index SNPs within ±100 kb were extracted. Then the posterior probability of co-localization was 1304 
calculated including eQTLs within the cis-window (±1 Mb from the transcription start site) for 1305 
each gene using the R coloc package24 with default values for the three prior probabilities. The 1306 
methods for trans-eQTL annotation are reported in the Supplementary Note. 1307 
 1308 
Experimental study 1309 
Promoter binding site predictions. For promoter binding site predictions, we used the 1310 
JASPAR 2018 database97,98. The frequency matrices were downloaded for transcription factor 1311 
binding sites of both vertebrate and human sequences (HNF1A: MA0046.1 and MA0046.2; 1312 
HNF4A: MA0114.1 and MA0114.2). These matrices were then used to query the promoter 1313 
region of ABCG2 (-1285/+362, or base pairs upstream of the transcription start site / and 1314 
downstream after transcription start site)99 by means of the LASAGNA 2.0 transcription factor 1315 
binding site search tool with default parameters and a P-value cutoff of 0.01100.  1316 
Site-directed mutagenesis. HNF1A and HNF4A clones were purchased from 1317 
GeneCopoeia (EX-A7792-M02 and EX-Z5283-M02, respectively) and were mutagenized using 1318 
the QuikChange Lightning Site Directed Mutagenesis kit (Agilent Technologies, #210518) per 1319 
manufacturer’s instructions using PAGE purified primers, which are reported in the 1320 
Supplementary Note.  1321 
Luciferase assay. HEK293T cells were seeded in white-walled 96-well plates coated with 1322 
Poly-L-lysine at roughly 12,500 cells per well. Cells were transfected 18 hours later with either 1323 
the ABCG2 promoter (-1285/+362) upstream of a firefly luciferase in the pGL4.14 vector (a 1324 
generous gift from Douglas D. Ross, University of Maryland School of Medicine), or the pGL4.14 1325 
vector (Promega, #E699A) without promoter construct, as well as GFP expressing vector used 1326 
as an internal negative control (pEGFP-C1, Clontech)101 using X-tremeGeneTM 9 DNA 1327 
Transfection Reagent (Roche Diagnostics, #6365787001). Transfection cocktails were prepared 1328 
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per manufacturer’s specifications either with or without transcription factor using the following 1329 
ratio: 0.6 μg promoter construct, 0.2, 0.1, or 0.05 μg transcription factor, and 0.05 μg GFP. 1330 
When no transcription factor was used, pcDNA3.1 was substituted. Approximately 48 hours 1331 
after transfection, cells were rinsed with 1x PBS, then lysed using Passive Lysis Buffer (Promega 1332 
#E194A) for 15 minutes. During this incubation, GFP measurements were taken using a 1333 
CLARIOstar microplate reader (BMG Labtech). Next, 30 μl of Luciferase Reagent (Promega, 1334 
E297A&B) were added to each well, and the plate was incubated for an additional 20 minutes 1335 
at room temperature. Finally, luciferase activity was measured using the CLARIOstar microplate 1336 
reader taking the average over 6 seconds. To evaluate the significance of transactivation of the 1337 
ABCG2 promoter, we compared cells expressing transcription factors to those transfected with 1338 
the empty vector (pcDAN3.1) and to evaluate TF dose responses or differences in TF variants all 1339 
experimental conditions from one plate were compared using an Ordinary one-way ANOVA, 1340 
accounting for multiple comparisons with a Tukey’s multiple comparison test. Statistical 1341 
analysis was performed using Prism 7 (GraphPad Software Inc, USA). 1342 
Western blots. Equal volumes of deoxycholate-RIPA buffer were added to wells 1343 
containing desired lysates following the luciferase assay and plates were then incubated at 4 °C 1344 
overnight. Equal volumes of sample + 5x SDS loading dye + 10% ߚ-merceptoethanol were then 1345 
loaded into 10% Mini-PROTEAN® TGX Stain-Free™ Precast Gels (Bio-Rad, #4568033) and run per 1346 
manufacturer’s specifications. Gels were then cross-linked for 45 seconds and imaged to reveal 1347 
total protein load, which was used as the loading control for each lane (representative images 1348 
of these protein gels are found in Supplementary Fig. 8). Gels were then transferred onto 1349 
nitrocellulose membranes using the Trans-Blot® Turbo™ Transfer System (Bio-Rad), blocked for 1350 
2 hours at room temperature in 5% milk in TBS-T, and incubated overnight at 4 °C with primary 1351 
antibody. Membranes were then washed 3 times with TBS-T, incubated at room temperature 1352 
for 1 hour with Donkey anti-rabbit secondary antibody (Jackson ImmunoResearch, #111-035-1353 
144) diluted 1:5,000 in 2.5% milk in TBS-T. Membranes were then washed again and developed 1354 
using SuperSignal™ West Pico PLUS Chemiluminescent Substrate (Thermo Scientific, #34577) 1355 
and imaged on the ChemiDoc MP imaging system (Bio-Rad). All primary antibodies were diluted 1356 
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1:1,000 in 2.5% milk in TBS-T. Antibodies used included HNF4α (Cell Signaling Technology, 1357 
#3113) and HNF1α (Cell Signaling Technology, #89670). Antibodies were validated using lysates 1358 
of overexpressing HEK293T cells transfected with either HNF construct, demonstrating bands at 1359 
the appropriate sizes (Supplementary Fig. 8). 1360 
 1361 
Reporting Summary. Further information on research design is available in the Nature 1362 
Research Reporting Summary linked to this article.1363 
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 1364 
Data availability 1365 
Genome-wide summary statistics for this study are shared at http://ckdgen.imbi.uni-freiburg.de 1366 
and will be made publicly available through dbGaP accession number phs000930.v6.p1. 1367 
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Editorial summary: 1465 
A trans-ethnic genome-wide association study of serum urate levels identifies 183 loci influencing this 1466 
trait. Enrichment analyses, fine mapping and co-localization with gene expression in 47 tissues implicate 1467 
kidney and liver as key target organs and prioritize potential causal genes. 1468 
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